Accessibility Tools
Invert colors
Monochrome
Dark contrast
Light contrast
Low saturation
High saturation
Highlight links
Highlight headings
Screen reader
Read mode
Content scaling
100
%
Font size
100
%
Line height
100
%
Letter spacing
100
%
SEC Filings
SEC Filings
Year
2022
Date
06-13
Description
Other Definitive Proxy Statements
SEC Form
DEF 14A
Download Word
Download Excel
Download PDF
GeoVax_DEF_14A__2022_Annual_Meeting_.pdf
id
About GeoVax
Company
Board of Directors & Corporate Advisors
Scientific Advisory Board
Our Technology
MVA Technology Overview
Gedeptin® Technology Overview
Publications
Product Pipeline
Pipeline Summary
Oncology
Infectious Diseases
Search
About Us
Company
Leadership
Board of Directors & Corporate Advisors
Scientific Advisory Board
Technology
MVA Technology Overview
Gedeptin® Technology Overview
Publications
Pipeline
Pipeline Summary
Oncology
Infectious Diseases
Investors
Corporate Profile
Press Releases
Media
Events & Presentations
SEC Filings
GeoVax Stock Information
Corporate Governance
Analyst Coverage
Investor FAQ's
Careers
Contact
